Audientes AS (AUDNTS)

Currency in DKK
0.002
0.000(0.00%)
Closed·
Showing Audientes AS historical data. For real-time data please try another search
Fair Value
Day's Range
0.0020.002
52 wk Range
0.0010.036
Key Statistics
Bid/Ask
0.002 / 0.002
Prev. Close
0.002
Open
0.002
Day's Range
0.002-0.002
52 wk Range
0.001-0.036
Volume
-
Average Volume (3m)
2.1M
1-Year Change
-90.1961%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AUDNTS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Audientes AS News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Audientes AS Company Profile

Audientes A/S designs, develops, and markets hearing aids and assisted hearing solutions. The company provides self-fitting hearing aids, including the Ven product, for people with mild to severe hearing loss. It offers the Audientes app for Android and iOS devices, enabling users to personalize their hearing experience, generate audiograms, create hearing profiles, adjust sound settings, and store custom programs in the cloud. The hearing aids feature Bluetooth connectivity for integration with smartphones, televisions, and other Bluetooth-enabled devices, supporting phone calls and music streaming. Additional resources include guides on hearing aid features, hearing tests that can be performed at home or on the device, and customer support through certified partners and experience centers. The company serves audiology clinics, professionals such as ear doctors, ENTs, otologists, audiologists, and individuals with hearing loss. The company was founded in 2014 and is based in Horsholm, Denmark.

Audientes AS Earnings Call Summary for Q2/2025

  • Q2 2025 results: Modest revenue, EBITDA -3.1M DKK, negative equity of -1.2M DKK after debt-to-equity conversion
  • Stock price fell 10.53% post-earnings; down 82.95% YTD, reflecting investor concerns over financial health
  • Company aims for cash flow breakeven by end of 2026, exploring funding options including corporate bond issuance
  • Focus on product expansion, entering new markets, and preparing for medical device approvals in China
  • CEO highlights company as market challenger, anticipating revenue inflection point despite current financial challenges
Last Updated: 2025-09-02, 07:56 a/m
Read Full Transcript

Compare AUDNTS to Peers and Sector

Metrics to compare
AUDNTS
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x−0.6x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x2.6x
Price / LTM Sales
0.0x0.0x3.4x
Upside (Analyst Target)
0.0%0.0%41.1%
Fair Value Upside
Unlock0.0%5.3%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
421.00K / --
EPS Revisions
Last 90 days

AUDNTS Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.